1. Home
  2. ADVB vs XBIO Comparison

ADVB vs XBIO Comparison

Compare ADVB & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADVB

Advanced Biomed Inc.

HOLD

Current Price

$4.59

Market Cap

7.4M

Sector

Health Care

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.00

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADVB
XBIO
Founded
2014
N/A
Country
United States
United States
Employees
31
2
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
6.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADVB
XBIO
Price
$4.59
$3.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.9K
14.2K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
$1.26
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.90
52 Week High
$7.70
$13.93

Technical Indicators

Market Signals
Indicator
ADVB
XBIO
Relative Strength Index (RSI) 55.38 40.73
Support Level $3.71 $2.56
Resistance Level $5.59 $2.79
Average True Range (ATR) 0.47 0.18
MACD 0.05 -0.02
Stochastic Oscillator 78.57 5.47

Price Performance

Historical Comparison
ADVB
XBIO

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: